Log In Sign up
The largest database of trusted experimental protocols

Actrapid hm human insulin

Manufactured by Novo Nordisk
Visit Supplier
Sourced in Denmark

Actrapid HM is a human insulin product manufactured by Novo Nordisk. It is a short-acting insulin used to control blood sugar levels. The core function of Actrapid HM is to provide insulin for individuals with diabetes.

Automatically generated - may contain errors

Lab products found in correlation

Accu chek aviva blood glucose monitor, by Roche (2 mentions)

Close spelling variants of this product

Actrapid human insulin Actrapid HM Insulin Actrapid Actrapid Human insulin Insulin

2 protocols using actrapid hm human insulin

1

Insulin Sensitivity Assay in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
After 8 weeks on the diets, mice were fasted for 4–5 h in the middle of the dark phase with ad libitum access to water. Actrapid HM human insulin (Novo Nordisk, Denmark) was injected intraperitoneally (IP), and tail blood glucose levels were monitored at the time points indicated using the Accu-Chek Aviva blood glucose monitor (Roche, Switzerland). The Insulin dose was 0.4 and 0.8 mU/g body weight for CD and HFD fed mice, respectively.
Ramachandran D., Clara R., Fedele S., Hu J., Lackzo E., Huang J.Y., Verdin E., Langhans W, & Mansouri A. (2017). Intestinal SIRT3 overexpression in mice improves whole body glucose homeostasis independent of body weight. Molecular Metabolism, 6(10), 1264-1273.
+ Open protocol
+ Expand
2

Fasted Mouse Insulin Tolerance Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice were fasted for 5–6 h in the middle of the dark phase with ad libitum access to water. Actrapid HM human insulin (Novo Nordisk) was injected intraperitoneally (IP), and tail blood glucose was monitored at the indicated time points using the Accu-Chek Aviva blood glucose monitor (Roche). Insulin dose: 0.4 mU/g body weight (CD) and 0.8 mU/g body weight (HFD)19 (link).
Ramachandran D., Clara R., Fedele S., Michel L., Burkard J., Kaufman S., Diaz A.A., Weissfeld N., De Bock K., Prip-Buus C., Langhans W, & Mansouri A. (2018). Enhancing enterocyte fatty acid oxidation in mice affects glycemic control depending on dietary fat. Scientific Reports, 8, 10818.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!